Home | Business News | Browse by Publication | B | Business Wire

Aphios Corporation Executes Collaborative R&D Agreement with VivaCell Biotechnology EspaSa to Develop Combination Therapy For HIV Latency.

Publication: Business Wire
Publication Date: 24-MAR-09
Format: Online
Delivery: Immediate Online Access

Article Excerpt
WOBURN, Mass. -- Aphios Corporation today announced entering into a Collaborative Research and Development Agreement with VivaCell Biotechnology EspaSa S.L., Cordoba, Spain to develop a combination therapy for the treatment of HIV latency.

Currently, over 22 million people have died from AIDS and there are over 42 million people living with HIV/AIDS worldwide. There is no vaccine against HIV, and AIDS, if untreated, will lead to...



More articles from Business Wire
Xcellerex, Collaborators Receive $11 Million Phase 2 U.S. Contract to ..., March 24, 2009
The OAUG Announces Formation of New Oracle Applications User Group., March 24, 2009
GE Energy Chosen by Pepco Holdings to Deliver Smart Meters, Enabling C..., March 24, 2009
Hublot Turns to WISekey's Smartcard Technology to Fight Counterfeiting..., March 24, 2009
Contract Award: Gibbs & Cox, Inc., Class Design Agent for the Lockheed..., March 24, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.